Please ensure Javascript is enabled for purposes of website accessibility

Regeneron and Roche Team Up to Triple Production of COVID-19 Treatment

By Eric Volkman - Aug 19, 2020 at 4:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Regeneron's REGN-COV2 is a leading candidate to treat the illness.

Regeneron's (REGN -1.81%) COVID-19 treatment candidate is getting a big boost from Roche (RHHBY 0.77%). The two companies announced in a joint press release Wednesday that they are collaborating on the development of the former's REGN-COV2, and will together manufacture and distribute it if it wins approval from regulators.

The pair said that by combining their efforts, the supply of the treatment could be ramped up by at least three and a half times current capacity. They added that there is potential for further increases.

A masked child getting a jab from a medical professional.

Image source: Getty Images.

REGN-COV2, which is a dual antibody "cocktail," is being investigated as both a drug to treat active COVID-19 cases and as a preventive medicine. It is currently undergoing two phase 2/3 clinical trials for the former and a single phase 3 for the latter. This makes REGN-COV2 one of the more advanced COVID-19 candidates and has tagged Regeneron as a leading coronavirus stock.

The company is included in the government's Warp Speed program, which provides federal monetary and resource support for developers of COVID-19 vaccine candidates.

If REGN-COV2 proves efficacious and is approved for use, Regeneron would distribute it in the U.S., and Roche would do so for the rest of the world.

Roche CEO Bill Anderson was quoted as saying that his company is "committing our manufacturing expertise and capacity, and our global distribution network to bring Regeneron's potential antibody combination to as many people around the world as we possibly can."

Investors were clearly pleased by the companies' latest news. On Wednesday, as the S&P 500 index fell, shares of Regeneron rose to close 1.8% higher, while Roche stock ticked up 0.6%.

 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.96 (0.77%) $0.32
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$624.83 (-1.81%) $-11.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.